Download
00415_2024_Article_12647.pdf 991,82KB
WeightNameValue
1000 Titel
  • GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
1000 Autor/in
  1. Katzdobler, Sabrina |
  2. Nübling, Georg |
  3. Klietz, Martin |
  4. Fietzek, Urban M. |
  5. Palleis, Carla |
  6. Bernhardt, Alexander M. |
  7. Wegner, Florian |
  8. Huber, Meret |
  9. Rogozinski, Sophia |
  10. Schneider, Luisa-Sophie |
  11. Spruth, Eike Jakob |
  12. Beyle, Aline |
  13. Vogt, Ina R. |
  14. Brandt, Moritz |
  15. Hansen, Niels |
  16. Glanz, Wenzel |
  17. Brockmann, Kathrin |
  18. Spottke, Annika |
  19. Hoffmann, Daniel C. |
  20. Peters, Oliver |
  21. Priller, Josef |
  22. Wiltfang, Jens |
  23. Düzel, Emrah |
  24. Schneider, Anja |
  25. Falkenburger, Björn |
  26. Klockgether, Thomas |
  27. Gasser, Thomas |
  28. Nuscher, Brigitte |
  29. Haass, Christian |
  30. Höglinger, Günter |
  31. Levin, Johannes |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-10
1000 Erschienen in
1000 Quellenangabe
  • 271(10):6991-6999
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00415-024-12647-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447157/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive neuronal cell loss and concomitant astrocytosis. Here, we investigate glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as fluid biomarkers for differential diagnosis, assessment of clinical disease severity and prediction of disease progression in MSA.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>GFAP and NfL levels were analyzed in plasma and CSF samples of 47 MSA patients as well as 24 Parkinson’s disease (PD) and 25 healthy controls (HC) as reference cohorts. In MSA, biomarker levels were correlated to baseline and longitudinal clinical disease severity (UMSARS scores).</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>In MSA, GFAP levels in CSF and plasma predicted baseline clinical disease severity as indicated by UMSARS scores, while NfL levels predicted clinical disease progression as indicated by longitudinal changes in UMSARS scores. Cross-sectionally, NfL levels in CSF and plasma were significantly elevated in MSA compared to both PD and HC. Receiver operating curves (ROC) indicated high diagnostic accuracy of NfL for distinguishing MSA from PD (CSF: AUC = 0.97, 95% CI 0.90–1.00; plasma: AUC = 0.90, 95% CI 0.81–1.00).</jats:p> </jats:sec><jats:sec> <jats:title>Discussion</jats:title> <jats:p>In MSA, GFAP shows promise as novel biomarker for assessing current clinical disease severity, while NfL might serve as biomarker for prediction of disease progression and differential diagnosis of MSA against PD.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Fluid biomarkers
lokal Parkinson Disease/blood [MeSH]
lokal Disease Progression [MeSH]
lokal Neurofilament Proteins/cerebrospinal fluid [MeSH]
lokal Aged [MeSH]
lokal Neurofilament light chain
lokal Neuroinflammation
lokal Multiple system atrophy
lokal Glial fibrillary acidic protein
lokal Diagnosis, Differential [MeSH]
lokal Male [MeSH]
lokal Neurofilament Proteins/blood [MeSH]
lokal Glial Fibrillary Acidic Protein/cerebrospinal fluid [MeSH]
lokal Multiple System Atrophy/blood [MeSH]
lokal Multiple System Atrophy/diagnosis [MeSH]
lokal Female [MeSH]
lokal Biomarkers/blood [MeSH]
lokal Humans [MeSH]
lokal Severity of Illness Index [MeSH]
lokal Glial Fibrillary Acidic Protein/blood [MeSH]
lokal Middle Aged [MeSH]
lokal Cross-Sectional Studies [MeSH]
lokal Parkinson Disease/diagnosis [MeSH]
lokal Biomarkers/cerebrospinal fluid [MeSH]
lokal ROC Curve [MeSH]
lokal Parkinson Disease/cerebrospinal fluid [MeSH]
lokal Multiple System Atrophy/cerebrospinal fluid [MeSH]
lokal Short Commentary
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2F0emRvYmxlciwgU2FicmluYQ==|https://frl.publisso.de/adhoc/uri/TsO8YmxpbmcsIEdlb3Jn|https://frl.publisso.de/adhoc/uri/S2xpZXR6LCBNYXJ0aW4=|https://frl.publisso.de/adhoc/uri/RmlldHplaywgVXJiYW4gTS4=|https://frl.publisso.de/adhoc/uri/UGFsbGVpcywgQ2FybGE=|https://frl.publisso.de/adhoc/uri/QmVybmhhcmR0LCBBbGV4YW5kZXIgTS4=|https://frl.publisso.de/adhoc/uri/V2VnbmVyLCBGbG9yaWFu|https://frl.publisso.de/adhoc/uri/SHViZXIsIE1lcmV0|https://frl.publisso.de/adhoc/uri/Um9nb3ppbnNraSwgU29waGlh|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBMdWlzYS1Tb3BoaWU=|https://frl.publisso.de/adhoc/uri/U3BydXRoLCBFaWtlIEpha29i|https://frl.publisso.de/adhoc/uri/QmV5bGUsIEFsaW5l|https://frl.publisso.de/adhoc/uri/Vm9ndCwgSW5hIFIu|https://frl.publisso.de/adhoc/uri/QnJhbmR0LCBNb3JpdHo=|https://frl.publisso.de/adhoc/uri/SGFuc2VuLCBOaWVscw==|https://frl.publisso.de/adhoc/uri/R2xhbnosIFdlbnplbA==|https://frl.publisso.de/adhoc/uri/QnJvY2ttYW5uLCBLYXRocmlu|https://frl.publisso.de/adhoc/uri/U3BvdHRrZSwgQW5uaWth|https://frl.publisso.de/adhoc/uri/SG9mZm1hbm4sIERhbmllbCBDLg==|https://frl.publisso.de/adhoc/uri/UGV0ZXJzLCBPbGl2ZXI=|https://frl.publisso.de/adhoc/uri/UHJpbGxlciwgSm9zZWY=|https://frl.publisso.de/adhoc/uri/V2lsdGZhbmcsIEplbnM=|https://frl.publisso.de/adhoc/uri/RMO8emVsLCBFbXJhaA==|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBBbmph|https://frl.publisso.de/adhoc/uri/RmFsa2VuYnVyZ2VyLCBCasO2cm4=|https://frl.publisso.de/adhoc/uri/S2xvY2tnZXRoZXIsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/R2Fzc2VyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/TnVzY2hlciwgQnJpZ2l0dGU=|https://frl.publisso.de/adhoc/uri/SGFhc3MsIENocmlzdGlhbg==|https://frl.publisso.de/adhoc/uri/SMO2Z2xpbmdlciwgR8O8bnRlcg==|https://orcid.org/0000-0001-5092-4306
1000 Hinweis
  • DeepGreen-ID: aa1a5563cdcc4e78974d59c8fd24e2eb ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Deutsche Forschungsgemeinschaft |
  2. Anton and Petra Ehrmann-Stiftung |
  3. Lüneburg Foundation |
  4. Klinikum der Universität München |
1000 Fördernummer
  1. -
  2. -
  3. -
  4. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsche Forschungsgemeinschaft |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Anton and Petra Ehrmann-Stiftung |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Lüneburg Foundation |
    1000 Förderprogramm -
    1000 Fördernummer -
  4. 1000 joinedFunding-child
    1000 Förderer Klinikum der Universität München |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6500107.rdf
1000 Erstellt am 2025-02-05T06:36:42.692+0100
1000 Erstellt von 322
1000 beschreibt frl:6500107
1000 Zuletzt bearbeitet 2025-09-14T08:35:17.301+0200
1000 Objekt bearb. Sun Sep 14 08:35:17 CEST 2025
1000 Vgl. frl:6500107
1000 Oai Id
  1. oai:frl.publisso.de:frl:6500107 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source